Cancer: Breakthrough Pain Clinical Trial
Official title:
Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients
34 adult (>18 years) cancer pain outpatients with Opioid base therapy because of pain and
breakthrough pain or extreme pain on movement will be included in this prospective,
randomized, double-blind crossover study.
Over a period of 3 weeks patients will go through 3 treatment arms, each one lasting one
week: Group A receives morphine drops and Placebo spray, Group B receives ketamine/chitosan
spray nasal and Placebo drops and Group C receives morphine drops and ketamine/chitosan spray
nasal.
Primary endpoint is time to onset of action of intranasal ketamine compared with morphine
drops. Secondary endpoint is the median numeric rating scale (NRS) improvement after using
the spray or morphine or the combination of ketamine spray and morphine drops.
n/a